Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.

[1]  R. Bristow,et al.  Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. , 2021, European urology.

[2]  M. Krause,et al.  Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response , 2021, Frontiers in Oncology.

[3]  A. Afshar-Oromieh,et al.  Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  R. Weichselbaum,et al.  (Oligo)metastasis as a Spectrum of Disease , 2021, Cancer Research.

[5]  A. Kishan,et al.  Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. , 2020, European urology focus.

[6]  P. Vermeulen,et al.  Stereotactic ablative radiation therapy to all lesions in patients with oligometastatic cancers: a phase I dose-escalation trial. , 2020, International journal of radiation oncology, biology, physics.

[7]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[8]  Sean S. Park,et al.  Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer , 2020, International journal of radiation oncology, biology, physics.

[9]  N. Lawrentschuk,et al.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.

[10]  B. Yaremko,et al.  Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.

[11]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[12]  A. Campbell,et al.  A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. , 2019, International journal of radiation oncology, biology, physics.

[13]  J. Lee,et al.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Wirth,et al.  Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? , 2019, European urology.

[15]  P. Boutros,et al.  What Is Oligometastatic Prostate Cancer? , 2019, European urology focus.

[16]  W. Everaerts,et al.  Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. , 2019, European urology oncology.

[17]  H. G. van der Poel,et al.  Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.

[18]  R. Weichselbaum,et al.  Oligometastatic prostate cancer: Reality or figment of imagination? , 2018, Cancer.

[19]  N. Lawrentschuk,et al.  Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.

[20]  L. Collette,et al.  Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. , 2018, The Lancet. Oncology.

[21]  U. Harmenberg,et al.  Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Treasure,et al.  Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017 .

[24]  G. Jenster,et al.  The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. , 2017, European urology.

[25]  J. Attia,et al.  Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  A. D'Amico,et al.  Adverse effects of androgen deprivation therapy and strategies to mitigate them. , 2015, European urology.

[27]  N. Lumen,et al.  Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancer , 2014, The Prostate.

[28]  T. Derlin,et al.  Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.

[29]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[30]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.